-$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter

Brokerages forecast that Kala Pharmaceuticals (NASDAQ:KALA) will post ($0.45) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.49). The company is scheduled to issue its next quarterly earnings report on Monday, June 25th.

On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.74). For the next year, analysts forecast that the company will post earnings of ($2.57) per share, with EPS estimates ranging from ($3.38) to ($1.93). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Kala Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings data on Monday, March 26th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.09).

KALA has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $46.00 price objective on shares of Kala Pharmaceuticals in a research note on Friday, December 22nd. BidaskClub raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Wells Fargo reaffirmed a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th. Finally, Zacks Investment Research raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $35.80.

Shares of KALA traded up $0.18 during trading hours on Friday, hitting $16.00. 193,093 shares of the company were exchanged, compared to its average volume of 327,168. The firm has a market cap of $393.88 and a PE ratio of -2.74. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.13. Kala Pharmaceuticals has a one year low of $11.81 and a one year high of $26.75.

In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc bought 75,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was acquired at an average price of $14.98 per share, with a total value of $1,123,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders bought 622,397 shares of company stock valued at $9,273,112.

Several institutional investors have recently modified their holdings of KALA. JPMorgan Chase & Co. acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $4,037,000. Bank of New York Mellon Corp acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $540,000. Farallon Capital Management LLC boosted its position in Kala Pharmaceuticals by 85.0% during the fourth quarter. Farallon Capital Management LLC now owns 185,000 shares of the company’s stock valued at $3,421,000 after purchasing an additional 85,000 shares during the last quarter. Emory University acquired a new stake in Kala Pharmaceuticals during the fourth quarter valued at $1,827,000. Finally, California State Teachers Retirement System acquired a new stake in Kala Pharmaceuticals during the third quarter valued at $301,000. 72.30% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “-$0.45 Earnings Per Share Expected for Kala Pharmaceuticals (KALA) This Quarter” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/20/0-45-earnings-per-share-expected-for-kala-pharmaceuticals-kala-this-quarter.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease.

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply